SCYNEXIS Completes Two Additional Clinical Studies Further

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078

SCY-078 demonstrates a low potential for certain drug-drug interactions – a relevant differentiator versus the azoles, the leading antifungal class – providing an opportunity for favorable labeling

Significant step forward to further de-risk the ongoing development program of SCY-078

JERSEY CITY, N.J., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc.  (Nasdaq: SCYX ) today announced the completion of two additional Drug-Drug Interaction (DDI) studies, further demonstrating the favorable safety profile of SCY-078.

An important milestone in drug development is to understand the potential impact of how two or more drugs interact with each other.  Patients with invasive fungal infections are typically immuno-compromised and are commonly treated for long periods of time with multiple concomitant drugs for their underlying conditions.  The potential for DDIs in these patients results in labeling restrictions, as is the case for the azole class of antifungals, which is associated with a high degree of DDIs with many commonly prescribed drugs.

To date, SCY-078 has been evaluated in multiple in vitro studies and Phase 1 clinical trials to assess the potential for SCY-078 to cause DDIs and to interfere with CYP liver enzymes, that are responsible for the metabolism of most drugs.

  • Based on in vitro studies conducted with a broad range of CYP enzymes, SCY-078 showed minimal interference with most enzymes, either as a direct inhibitor or inducer, including CYP3A enzymes, the most common pathway for the metabolism of many drugs. CYP2C8 enzyme was shown to be the enzyme with a higher risk of being inhibited by SCY-078;
  • DDI rosiglitazone clinical study to evaluate CYP2C8 inhibition : rosiglitazone, an antidiabetic medication, is very sensitive to inhibition of CYP2C8 and was used as an indicator of the maximum potential for clinical interaction with oral SCY-078. This study showed that SCY-078 had no effect on rosiglitazone blood levels when co-administered (i.e., no meaningful interaction was observed), indicating a low risk of clinical interactions with drugs metabolized via CYP enzymes;  
  • DDI tacrolimus clinical study : tacrolimus is an anti-rejection drug commonly used for bone marrow and solid organ transplants patients.  Several antifungals, specifically the azoles, induce an increase of tacrolimus blood levels (typically from two- to four-fold), resulting in toxicity concerns which frequently limits the use of the antifungals, and can require major tacrolimus dose adjustments.  In this study, oral SCY-078 had no effect on the maximum tacrolimus blood levels (no change in C max ) with only a minor effect on tacrolimus’ AUC.  These results suggest a low risk of clinical interactions and support the ability of co-administration of both drugs.

“These results provide further evidence of the favorable safety profile of SCY-078 and suggest that SCY-078 has low risk for causing clinically relevant drug interactions,” said Dr. David Angulo, Chief Medical Officer of SCYNEXIS. “Given the importance of drug co-administration for these vulnerable patients and the high risk for DDIs associated with the azoles – the only orally available antifungal class – we believe these data confirm the potential for SCY-078 to become a much-needed, potent, safe, flexible, and easy to administer antifungal alternative for these life-threatening fungal infections. This is another step towards completing our registration package and enabling a broad patient population to be included in our upcoming registration trials.”

About SCY-078

SCY-078 is an oral and IV glucan synthase inhibitor in Phase 2 clinical development for the treatment for fungal infections caused by  Candida  and  Aspergillus  species. SCY-078 is a semi-synthetic triterpene derivative of the natural product enfumafungin—a structurally distinct class of glucan synthase inhibitor. SCY-078 combines the broad spectrum antifungal activity of the Polyenes, the well-established safety profile of the Echinocandins and the flexibility of use (IV and oral formulations) of the Azoles. By belonging to a chemical class distinct from other antifungals, SCY-078 has shown  in vitro  and  in vivo  activity against multi-drug resistant pathogens, including azole and echinocandin resistant strains. Positive results from a recently reported Phase 2 proof-of-concept study in a mucocutaneous Candida  spp. infection (vulvovaginal candidiasis) provided evidence of the antifungal activity of orally administered SCY-078 in patients with  Candida  infections. The U.S. Food and Drug Administration (FDA) granted Fast Track, Qualified Infectious Disease Product (QIDP) and orphan drug designations (ODD) for the oral and IV formulations of SCY-078 for the indications of invasive Candida  infections (including candidemia) and invasive  Aspergillus  infections.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit  www.scynexis.com .

Forward Looking Statement

Statements contained in this press release regarding the expected low risk of DDIs with SCY-078are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to a number of factors, including:  the risk that results in in vitro studies may not be repeated in clinical trials; and the risk that unexpected events or results may occur. These risks and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Media Relations Blair Atkinson MacDougall Biomedical Communications Tel: 781.235.3060 batkinson@macbiocom.com Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 susan@argotpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 94

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 130

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 29

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 72

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 0

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 10

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 50

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading

Top 5 Most Recently Viewed Articles

GENFIT Achieves Milestone with EU Approval for Iqirvo®

Updated Category News Views 121

GENFIT Secures EU Approval for Iqirvo® GENFIT, a leading biopharmaceutical firm, has proudly announced that it received conditional approval from the European Commission for its medication Iqirvo® (elafibranor) at an 80mg dosage. This remarkable treatment is tailored for adults dealing with Primary Biliary Cholangitis (PBC) and is intended to be used in conjunction with...

Continue Reading
Yellow Pages Limited Q3 2025: Financial Highlights and Future Outlook

Updated Category News Views 252

Overview of Yellow Pages Limited's Financial Performance Yellow Pages Limited (TSX: Y), a notable player in the Canadian digital media and marketing landscape, has recently announced its financial results for the third quarter of 2025. The company showcases solid profitability and remains committed to its growth strategies. During this quarter, Yellow Pages Limited...

Continue Reading
Prosus's Major Move: Acquiring Despegar for $1.7 Billion

Updated Category News Views 230

Prosus's Strategic Acquisition of Despegar Prosus (OTC: PROSF) NV, recognized as a leading global technology investor, has revealed its intention to acquire Despegar (NYSE: DESP), a prominent online travel agency in Latin America, for an impressive sum of $1.7 billion. Under the terms of this agreement, shareholders of Despegar will benefit from a payment of $19.50 per...

Continue Reading
Discover Roof AI: Revolutionizing Roof Visualization for All

Updated Category News Views 207

Introducing Roof AI: The Future of Roof Visualization Roof AI has emerged as an innovative solution, especially after the successful launches of Remodel AI and Paint AI. It's designed to bring a significant transformation in how homeowners, contractors, designers, and roofing manufacturers visualize roofs before making any decisions. Whether you're planning a roof...

Continue Reading
Associa Celebrates Employee Recognition in National Awards

Updated Category News Views 240

Associa's Remarkable Achievement in Workplace Recognition Associa, a leader in community association management, proudly shares its recognition as a 2024 winner of the prestigious Best and Brightest Companies to Work for in the Nation. This accolade marks an impressive sixth recognition for the company, a testament to its unwavering dedication to cultivating an innovative...

Continue Reading